A new generation of
AI-enabled therapeutics
Ailux’s AI-powered biologics pipeline is focused on developing differentiated and convenient therapies for underserved patients.
Ongoing advances across our platform continue to unlock new possibilities for future therapeutic innovation.
- IMMUNOLOGY AND INFLAMMATION
ALX001 is a potentially best-in-class, AI-enabled bispecific antibody designed to simultaneously block two key drivers (TL1A/IL-23p19) of inflammatory bowel disease (IBD). Its novel mechanism of action supports ultra-low immunogenicity risk and potent TL1A inhibition. ALX001 has the potential to deliver superior therapeutic benefits with convenient dosing for IBD patients.
ALX002 is a potentially best-in-class, AI-optimized, dual-targeted (CD19/BCMA) T-cell engager designed for the treatment of B cell-mediated autoimmune diseases. Ailux’s proprietary CD3 masking technology enables a broader therapeutic window with potential to deliver safer immune reset and convenient dosing.
ALX005 is a potentially best-in-class, long-acting FcRn-blocking antibody designed to treat IgG-mediated autoimmune diseases with less frequent dosing. Our AI-enabled design precisely achieves durable and greater IgG clearance while maintaining a favorable preclinical safety profile.
A suite of wholly owned undisclosed AI-native programs across multiple therapeutic areas.
